Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Lung Cancer
Interventions
DRUG

carboplatin

Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)

DRUG

docetaxel

75 mg/m² intravenously, once, every 3 weeks

Trial Locations (1)

27599

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER